Dr Toni Choueiri speaks to ecancer about the phase 3 LITESPARK-005 study comparing belzutifan with everolimus in pretreated advanced clear cell renal cell carcinoma, data from which he presented at ESMO 2023.

Belzutifan is an oral inhibitor that targets HIF-2α. It is approved in the US for patients with VHL disease-associated RCC, pNET, and CNS haemangioblastoma.

During his presentation, Dr Choueiri highlighted that belzutifan had a statistically significant improvement in PFS and ORR compared to everolimus for patients with advanced ccRCC after immune checkpoint and anti-angiogenic therapies.

Furthermore, the safety profile of belzutifan was consistent with prior reports, and no new safety signals were observed.

Read the full story here.